How Pharma Medical Regulatory Review Cycles Shape Design System Governance

Pharma regulatory review cycles unintentionally influence design system governance by rewarding consistency, discouraging iteration, and prioritizing auditability over adaptability. Over time, this shifts design systems from enablement platforms into risk-management mechanisms. High-performing organizations address this by aligning governance models to regulatory realities—without allowing regulation to dictate user experience outcomes.